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Although established antiepilepsy drugs (AEDs) are
efﬁcacious and new drugs have become available
to treat patients with epilepsy, at least 30% of all
patients remain refractory to available treatment.1
Continued efforts to identify and develop new com-
pounds for the treatment of epilepsy motivate all
concerned because of the plight of so many pa-
tients. In the following sections, data are provided
that document the US experience in the develop-
ment and ultimate availability of zonisamide for
treatment of patients with partial seizures.
Development of zonisamide in the United States
began in 1982 as a collaborative project between
Dainippon Pharmaceuticals Co, and Parke–Davis.
Pilot studies of bioavailability and pharmacokinet-
ics involved about 270 healthy volunteers and also
patients with epilepsy. Both open and controlled
protocols that were performed in the mid-1980s
suggested that zonisamide had efﬁcacy for treat-
ment of patients with refractory partial seizures.2,3
However, drug development in the United States
was halted when 3.7% of patients enrolled in stud-
ies developed renal calculi. Since studies in Europe
and Japan showed both efﬁcacy and safety4,5 with
lower rates of calculi formation, studies in the US
were resumed in the 1990s.
As detailed in the following reports, bioavailabil-
ity and bioequivalence were evaluated in ﬁve stud-
ies of 72 patients and healthy volunteers aged 19–69
years. Fourteen studies of 172 patients and healthy
volunteers aged 18–71 years reported the effects of
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other drugs including AEDs, and both food and re-
nal function on zonisamide pharmacokinetics. Data
showed that plasma clearance of zonisamide is in-
creased when administered along with other drugs
that induce hepatic enzymes. Zonisamide kinetics
are similar in young and elderly patients and are
unaffected by food. Decline of renal function is
associated with decreased zonisamide clearance.
Plasma half-life of zonisamide measured in healthy
volunteers given 400mg/day was reported to be
63–69 h.6 Because of drug interactions, the half-life
of zonisamide is signiﬁcantly decreased in patients
treated with phenytoin, carbamazepine, phenobar-
bital, or valproate.2
As reviewed in detail by Dr. Faught in this doc-
ument, clinical trials studied 810 patients aged
12—79 years. Many patients were treated for more
than 1 year in follow-on open-label studies. Me-
dian seizure frequency was reduced from 13.9 to
50.1%. Responder rates, an expression of the per-
cent of patients having a greater than 50% seizure
reduction, ranged from 28.0 to 55%. Open-label as-
sessment reported that a 52% reduction of seizures
from baseline was associated with a dosage of
500mg/day.3 The responder rate in this study was
41%. A European study reported an association of
a zonisamide plasma level of 30g/mL resulted
in a decrease of 27% in seizures of partial onset.4
A summary of data from 1008 patients treated in
various protocols in Japan reported doses ranging
from 5.9 to 8.2mg/kg per day resulted in a respon-
der rate of 50 to 60%.5 A multicenter randomized,
placebo–controlled study of patients with refrac-
tory partial-onset seizures reported ﬁrst dose efﬁ-
cacy of 100mg/day resulting in 20.5% reduction of
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seizures. A dose of 400mg/day resulted in a 42%
responder rate. Adverse events were infrequent
and the drug was well tolerated.7 Doses in adults of
400–600mg/day corresponded to 7mg/kg per day.
Adverse effects in studies showed that zon-
isamide causes weight loss and is associated with
the occurrence of somnolence, anorexia, and
ataxia. Renal calculi continued to be detected but
the percentage of all studied patients was low.
In 1997, as data collection from the US clinical
trials was completed, Dainippon entered into a li-
censing agreement with Elan Pharmaceuticals for
marketing and distribution of zonisamide in North
America and Europe. Zonisamide was approved for
use in the United States in March 2000.
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